Durable, safe and effective long-term kidney drug data from Tricida fuel blockbuster potential
Kidney drug developer Tricida’s shares shot up on Thursday, after long-term data highlighted its lead drug’s durable efficacy and safety profile as a treatment for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.